Kirin vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kirin Holdings Co. Ltd. (2503.JP)

Q3 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

September 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Latest6 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.